Alzheimer's disease is a condition that destroys brain cells. People with this disease slowly lose the ability to learn, function, and remember.
It is the most common cause of
dementia. Dementia is a loss in mental abilities that is great enough to interfere with daily life.
Areas of the Brain Affected by Alzheimer's Disease
There is no cure for Alzheimer's disease. There are no certain ways to slow its progression. Medication is available to treat some of the symptoms. The goal is to find a medication that can manage the symptoms or slow the condition's course.
Medications for Symptoms and Disease Progression
Medications that have been approved to reduce the symptoms of Alzheimer's disease include:
Caring for a person with Alzheimer's disease is difficult and exhausting. The primary caregiver needs emotional support, rest, and regular breaks. The
is an excellent resource for families and caregivers
Albanese E, Dangour AD, Uauy R, et al. Dietary fish and meat intake and dementia in Latin America, China, and India: A 10/66 Dementia Research Group population-based study.
Am J Clin Nutr.
Alzheimer dementia. EBSCO DynaMed website. Available at: ...(Click grey area to select URL) Updated March 31, 2014. Accessed August 18, 2014.
Alzheimer's disease medications fact sheet. National Institute on Aging website. Available at: ...(Click grey area to select URL) Accessed August 18, 2014.
Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: Meta-analysis of prospective studies.
Am J Geriatr Psychiatry.
Carillo MC, Blackwell A, Hampel H, et al. Early risk assessment for Alzheimer's disease.
Deweerdt S. Prevention: Activity is the best medicine.
Gidoni R, Benussi L, Paterlini A, Albertini V, Binetti G, Emanuele E. Cerebrospinal fluid biomarkers in Alzheimer’s disease: The present and the future.
Neurodegen Dis. 2011;8(6):413-420.
Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African-American relatives of patients with Alzheimer disease.
Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease: Academic, industry, and regulatory perspectives.
Nat Rev Drug Discov.
Hayden KM, Welsh-Bohmer KA. Epidemiology of cognitive aging and Alzheimer’s disease: Contributions of the Cache County Utah study of memory, health, and aging.
Curr Top Behav Neurosci. 2012;10:3-31.
Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer’s disease.
Curr Neurol Neurosci Rep.
Ruitenberg A, van Swieten JC, Wittemen JC, et al. Alcohol consumption and risk of dementia: The Rotterdam Study.
1/8/2010 DynaMed's Systematic Literature Surveillance. Available at: ...(Click grey area to select URL) Snitz BE, O'Meara ES, et al. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA. 2009;302(24):2663-2670.
5/4/2012 DynaMed's Systematic Literature Surveillance. Available at: ...(Click grey area to select URL) Buchman AS, Boyle PA, et al. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology. 2012;78(17):1323-1329.
9/3/2014 DynaMed's Systematic Literature Surveillance. Available at: ...(Click grey area to select URL) Wippold FJ, Brown DC, Broderick DF, et al. American College of Radiology (ACR) Appropriateness Criteria for dementia and movement disorders. Available at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/DementiaAndMovementDisorders.pdf. Updated 2014. Accessed September 3, 2014.